Journal of Clinical Endocrinology & Metabolism, Vol 80, 2638-2645, Copyright © 1995 by Endocrine Society

ARTICLES

Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids

S Mohan, C Libanati, C Dony, K Lang, N Srinivasan and DJ Baylink
Department of Medicine, Loma Linda University, California, USA.

Insulin-like growth factor binding proteins (IGFBPs) serve as transport proteins for the IGFs and modulate their biological effects. In order to evaluate the relative contribution of IGFBP-5 to the IGF binding capacity of serum and other biological fluids and to study more accurately the in vivo regulation of serum IGFBP-5, we have developed an RIA for IGFBP-5 using recombinant human IGFBP-5 as the antigen, tracer, and standard. The validity of the IGFBP-5 RIA was established from the following data: 1) recombinant human IGFBP-5 and purified human bone-derived IGFBP-5 inhibited the binding of tracer to the antisera in an identical manner; 2) the immunoreactive IGFBP-5 in serum co-migrated with recombinant human IGFBP-5 in both sodium dodecyl sulfate polyacrylamide gel electrophoresis and high performance gel filtration chromatography; 3) none of the other known IGFBPs (IGFBP-1, - 2, -3, -4, and -6) exhibited significant cross-reactivity; 4) the addition of IGF-I or IGF-II to the samples did not affect the recovery of IGFBP-5; and 5) the recovery of the exogenously added IGFBP-5 to serum was greater than 90%. In order to further validate our IGFBP-5 RIA, measurements of IGFBP-5 were carried out in the conditioned media samples collected from human bone cells treated with effectors that are known to influence IGFBP-5 production. Treatment of human bone cells with bone morphogenetic protein-7, which increases IGFBP-5 production, caused an increase in IGFBP-5 protein levels; dexamethasone, which decreases IGFBP-5 production, caused a decrease in IGFBP-5 protein levels measured in the conditioned medium by this RIA. Application of this RIA to the measurement of the IGFBP-5 level in human serum revealed that the circulating level of IGFBP-5 in healthy women decreased from 664 +/- 108 ug/L in prepubertal girls to 222 +/- 42 ug/L in women ages 61-85 yr (P < 0.001). There was also a small but significant decrease in the mean serum level of IGFBP-5 in women ages 23-39 yr compared with the level in prepubertal girls (589 +/- 66 vs. 664 +/- 108 ug/L, P < 0.05). Additional studies with this assay may provide an insight into the physiological mechanism that regulates IGFBP-5 production in vivo and the potential role of this protein as an IGF transport protein in serum and other biological fluids.

This article has been cited by other articles:

				H. Yasuoka, Z. Zhou, J. M. Pilewski, T. D. Oury, A. M.K. Choi, and C. A. Feghali-Bostwick Insulin-Like Growth Factor-Binding Protein-5 Induces Pulmonary Fibrosis and Triggers Mononuclear Cellular Infiltration Am. J. Pathol., November 1, 2006; 169(5): 1633 - 1642. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				A. Kumar, S. Mohan, J. Newton, M. Rehage, K. Tran, D. J. Baylink, and X. Qin Pregnancy-associated Plasma Protein-A Regulates Myoblast Proliferation and Differentiation through an Insulin-like Growth Factor-dependent Mechanism J. Biol. Chem., November 11, 2005; 280(45): 37782 - 37789. [Abstract] [Full Text] [PDF]

				M. J. E. Walenkamp, M. Karperien, A. M. Pereira, Y. Hilhorst-Hofstee, J. van Doorn, J. W. Chen, S. Mohan, A. Denley, B. Forbes, H. A. van Duyvenvoorde, et al. Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2855 - 2864. [Abstract] [Full Text] [PDF]

				R. P A Rooman, L. O. De Beeck, M. Martin, J. van Doorn, S. Mohan, and M. V L Du Caju Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature Eur. J. Endocrinol., April 1, 2005; 152(4): 597 - 604. [Abstract] [Full Text] [PDF]

				D. A. M. Salih, S. Mohan, Y. Kasukawa, G. Tripathi, F. A. Lovett, N. F. Anderson, E. J. Carter, J. E. Wergedal, D. J. Baylink, and J. M. Pell Insulin-Like Growth Factor-Binding Protein-5 Induces a Gender-Related Decrease in Bone Mineral Density in Transgenic Mice Endocrinology, February 1, 2005; 146(2): 931 - 940. [Abstract] [Full Text] [PDF]

				C A Sharp, S J Brown, M W J Davie, P Magnusson, and S Mohan Increased matrix concentrations of IGFBP-5 in cancellous bone in osteoarthritis Ann Rheum Dis, September 1, 2004; 63(9): 1162 - 1165. [Abstract] [Full Text] [PDF]

				C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF]

				S. Mohan, G. Masinde, X. Li, and D. J. Baylink Mapping Quantitative Trait Loci That Influence Serum Insulin-Like Growth Factor Binding Protein-5 Levels in F2 Mice (MRL/MpJ X SJL/J) Endocrinology, August 1, 2003; 144(8): 3491 - 3496. [Abstract] [Full Text] [PDF]

				R. C. Baxter, S. Meka, and S. M. Firth Molecular Distribution of IGF Binding Protein-5 in Human Serum J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 271 - 276. [Abstract] [Full Text] [PDF]

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				A. Eliakim, T. P. Scheett, R. Newcomb, S. Mohan, and D. M. Cooper Fitness, Training, and the Growth Hormone{->}Insulin-Like Growth Factor I Axis in Prepubertal Girls J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2797 - 2802. [Abstract] [Full Text] [PDF]

				R. Fernholm, M. Bramnert, E. Hägg, A. Hilding, D. J. Baylink, S. Mohan, and M. Thorén Growth Hormone Replacement Therapy Improves Body Composition and Increases Bone Metabolism in Elderly Patients with Pituitary Disease J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4104 - 4112. [Abstract] [Full Text]

				J. J. Smink, J. G. Koster, B. I. Hendriks-Stegeman, and S. C. van Buul-Offers Insulin-Like Growth Factor (IGF) II Induced Changes in Expression of IGF Binding Proteins in Lymphoid Tissues of hIGF-II Transgenic Mice Endocrinology, December 1, 1999; 140(12): 5876 - 5882. [Abstract] [Full Text]

				C. Richman, D. J. Baylink, K. Lang, C. Dony, and S. Mohan Recombinant Human Insulin-Like Growth Factor-Binding Protein-5 Stimulates Bone Formation Parameters in Vitro and in Vivo Endocrinology, October 1, 1999; 140(10): 4699 - 4705. [Abstract] [Full Text]

				C. Libanati, D. J. Baylink, E. Lois-Wenzel, N. Srinivasan, and S. Mohan Studies on the Potential Mediators of Skeletal Changes Occurring during Puberty in Girls J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2807 - 2814. [Abstract] [Full Text]

				G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]

				D. R. Powell, S. K. Durham, E. D. Brewer, J. W. Frane, S. L. Watkins, R. J. Hogg, and S. Mohan Effects of Chronic Renal Failure and Growth Hormone on Serum Levels of Insulin-Like Growth Factor-Binding Protein-4 (IGFBP-4) and IGFBP-5 in Children: A Report of the Southwest Pediatric Nephrology Study Group J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 596 - 601. [Abstract] [Full Text]

				A. Eliakim, J. A. Brasel, S. Mohan, W. L. T. Wong, and D. M. Cooper Increased physical activity and the growth hormone-IGF-I axis in adolescent males Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1998; 275(1): R308 - R314. [Abstract] [Full Text] [PDF]

				S. M. Twigg and R. C. Baxter Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit J. Biol. Chem., March 13, 1998; 273(11): 6074 - 6079. [Abstract] [Full Text] [PDF]

				G. L. Klein, S. E. Wolf, C. B. Langman, C. J. Rosen, S. Mohan, B. S. Keenan, S. Matin, C. Steffen, M. Nicolai, D. E. Sailer, et al. Effect of Therapy with Recombinant Human Growth Hormone on Insulin-Like Growth Factor System Components and Serum Levels of Biochemical Markers of Bone Formation in Children After Severe Burn Injury J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 21 - 24. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]